Business Information
The group’s principal activity is to manufacture formulated generic drugs. The group products include -ACA, Avecil and Clavulanate Potassium, Amoxicillin Clavulanate Potassium (5:1), Ceflriaxone for Injection, Amoxicillin Clavulanate Potassium (2:1), EPO, clavulanic acid, Mezlocillin, and Amoxicillin Sulbactam. The group operates through three segments namely chemical, pharma, and biotech division. The group operates from the United States. The group’s revenue in the year 2006 was $54,865,805.
|
|
|
Year |
Sales |
Net Income |
| 2006 | 54,866 | 4,535 | | 2005 | 56,245 | 183 | | 2004 | 3,705 | (943)
|
|
| TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
TO SEE COMPLETE RESULTS SUBSCRIBE NOW |
|
Click for more Executives |
|
|
